“Checkpoint inhibition has revolutionized oncology, but unfortunately many patients given the strongest forms of this cancer therapy will experience severe side effects,” said Aaron Newman, PhD. “We wanted to know if we could use data science to determine in advance who will be vulnerable to these toxicities.” Newman is the senior author on a paper describing this research, published in Nature Medicine.
